Quick Answer
Indaptus Therapeutics, Inc. reported Cash and Equivalents of $8.51 million for fiscal year 2025.
Indaptus Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.51M | +47.0% |
| 2024 | $5.79M | -56.7% |
| 2023 | $13.36M | +38.8% |
| 2022 | $9.63M | -75.4% |
| 2021 | $39.13M | +2289.8% |
| 2020 | $1.64M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.83M | -21.1% | -5.4% |
| June 30, 2025 | $6.16M | -15.7% | +58.3% |
| March 31, 2025 | $3.89M | -60.1% | -32.8% |
| December 31, 2024 | $5.79M | -56.7% | -21.6% |
| September 30, 2024 | $7.38M | -53.8% | +1.1% |
| June 30, 2024 | $7.30M | -42.5% | -25.0% |
| March 31, 2024 | $9.74M | +43.2% | -27.1% |
| December 31, 2023 | $13.36M | +38.8% | -16.3% |
- Indaptus Therapeutics, Inc. showed an increase of +47.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Indaptus Therapeutics, Inc.’s cash and equivalents has grown by 419.6% (from $1.64 million to $8.51 million).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: